elmiron
bene-arzneimittel gmbh - pentósani pólýsúlfatnatríum - blöðrubólga, millivefli - Þvaglát - elmiron er ætlað til meðferðar við þvagblöðruverkjum sem einkennist af annaðhvort glomerulations eða skaða hjá hunner hjá fullorðnum með miðlungsmiklum til alvarlegum verkjum, brýnt og tíðni micturition.
evra
gedeon richter plc. - norelgestromin, ethinyl estradiol - getnaðarvörn - hormón kynlíf og stillum kynfæri - konur getnaðarvörn. evra er ætlað konum frjósöm aldri. Öryggi og verkun hefur verið stofnað í konur á aldrinum 18 til 45 ára.
waylivra
akcea therapeutics ireland limited - volanesorsen járn - hyperlipoproteinemia type i - Önnur fitu breyta lyfjum - waylivra er ætlað sem viðbót til að mataræði í fullorðinn sjúklinga með erfðafræðilega staðfest ættingja chylomicronemia heilkenni (gegn) og í mikilli hættu fyrir lyf og sem svar við mataræði og þríglýseríða lækka meðferð hefur verið ófullnægjandi.
aripiprazole sandoz
sandoz gmbh - aripíprazól - schizophrenia; bipolar disorder - psycholeptics - aripiprazol sandoz er ætlað til meðferðar á geðklofa hjá fullorðnum og unglingum 15 ára og eldri. sjúklingum sandoz er ætlað fyrir meðferð í meðallagi til alvarlega oflæti þáttur í geðhvarfasýki ég ringulreið og til að fyrirbyggja nýja oflæti þáttur í fullorðnir sem upplifað aðallega oflæti þætti og sem oflæti þáttur brugðist við sjúklingum meðferð. sjúklingum sandoz er ætlað fyrir meðferð upp til 12 vikur í meðallagi að alvarlega oflæti þáttur í geðhvarfasýki ég röskun á unglingar eru 13 ára og eldri.
nuvaxovid
novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.
evusheld
astrazeneca ab - tixagevimab, cilgavimab - covid-19 virus infection - prevention of covid-19.
dutrebis
merck sharp dohme limited - áhrif, raltegravir kalíum - hiv sýkingar - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebis er ætlað ásamt öðrum anti‑retróveira lyf til meðferð hiv veira (hiv‑1) sýkingu í fullorðnir, unglingar, og börn frá 6 ára og vega að minnsta kosti 30 kg án staðar eða fortíð vísbendingar um friðhelgi andstöðu við veirum á höfða (integrase Þræði flytja hemil) og nrti (núkleósíð vixlrita hemil) flokkum (sjá kafla 4. 2, 4. 4 og 5.
bimervax
hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - bóluefni - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.